Griffin Asset Management Inc. Sells 19,902 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

Griffin Asset Management Inc. lessened its position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 7.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 237,547 shares of the company's stock after selling 19,902 shares during the period. Griffin Asset Management Inc. owned approximately 0.39% of Pulse Biosciences worth $4,136,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC purchased a new stake in Pulse Biosciences in the fourth quarter valued at approximately $193,000. Creative Planning raised its position in shares of Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company's stock valued at $384,000 after buying an additional 11,667 shares in the last quarter. Franklin Resources Inc. bought a new position in Pulse Biosciences in the third quarter valued at $378,000. Barclays PLC increased its position in shares of Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company's stock valued at $530,000 after purchasing an additional 23,738 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Pulse Biosciences during the 3rd quarter valued at about $588,000. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Price Performance

Shares of PLSE stock traded up $1.34 on Friday, hitting $21.00. 245,124 shares of the company's stock traded hands, compared to its average volume of 129,256. The company's fifty day simple moving average is $18.57 and its 200 day simple moving average is $17.76. Pulse Biosciences, Inc. has a one year low of $6.59 and a one year high of $22.69.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the company earned ($0.19) earnings per share.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Pulse Biosciences to a "sell" rating in a research note on Thursday, January 2nd.

Insider Buying and Selling

In related news, CEO Burke Thomas Barrett sold 50,000 shares of the company's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $17.42, for a total transaction of $871,000.00. Following the completion of the transaction, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. This represents a 44.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert W. Duggan purchased 55,256 shares of Pulse Biosciences stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the transaction, the director now directly owns 42,328,717 shares of the company's stock, valued at $727,207,358.06. This trade represents a 0.13 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 71.50% of the stock is owned by corporate insiders.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.